Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

A Revolution in Treatment for Hepatitis C Infection: Mitigating the Budgetary Impact.

Marseille E, Kahn JG.

PLoS Med. 2016 May 31;13(5):e1002031. doi: 10.1371/journal.pmed.1002031.

2.

The Cost of Intramedullary Nailing for Femoral Shaft Fractures in Dar es Salaam, Tanzania.

Kramer EJ, Shearer DW, Marseille E, Haonga B, Ngahyoma J, Eliezer E, Morshed S.

World J Surg. 2016 Sep;40(9):2098-108. doi: 10.1007/s00268-016-3496-z.

PMID:
26983603
3.

Estimated Costs for Delivery of HIV Antiretroviral Therapy to Individuals with CD4+ T-Cell Counts >350 cells/uL in Rural Uganda.

Jain V, Chang W, Byonanebye DM, Owaraganise A, Twinomuhwezi E, Amanyire G, Black D, Marseille E, Kamya MR, Havlir DV, Kahn JG.

PLoS One. 2015 Dec 3;10(12):e0143433. doi: 10.1371/journal.pone.0143433.

4.

Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.

Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, Kahn JG.

JAMA Intern Med. 2016 Jan;176(1):65-73. doi: 10.1001/jamainternmed.2015.6011.

5.

Are long-lasting insecticide-treated bednets and water filters cost-effective tools for delaying HIV disease progression in Kenya?

Verguet S, Kahn JG, Marseille E, Jiwani A, Kern E, Walson JL.

Glob Health Action. 2015 Jun 10;8:27695. doi: 10.3402/gha.v8.27695.

6.

Thresholds for the cost-effectiveness of interventions: alternative approaches.

Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S.

Bull World Health Organ. 2015 Feb 1;93(2):118-24. doi: 10.2471/BLT.14.138206.

7.

Avahan and the cost-effectiveness of "prevention as prevention".

Marseille E, Kahn JG.

Lancet Glob Health. 2014 Sep;2(9):e493-4. doi: 10.1016/S2214-109X(14)70295-5. No abstract available.

8.

Global cost-effectiveness of GDM screening and management: current knowledge and future needs.

Weile LK, Kahn JG, Marseille E, Jensen DM, Damm P, Lohse N.

Best Pract Res Clin Obstet Gynaecol. 2015 Feb;29(2):206-24. doi: 10.1016/j.bpobgyn.2014.06.009. Review.

PMID:
25225056
9.

Essential surgery is cost effective in resource-poor countries.

Marseille E, Morshed S.

Lancet Glob Health. 2014 Jun;2(6):e302-3. doi: 10.1016/S2214-109X(14)70236-0. No abstract available.

10.

Scaling up integrated prevention campaigns for global health: costs and cost-effectiveness in 70 countries.

Marseille E, Jiwani A, Raut A, Verguet S, Walson J, Kahn JG.

BMJ Open. 2014 Jun 26;4(6):e003987. doi: 10.1136/bmjopen-2013-003987.

11.

Estimating the cost-effectiveness of nutrition supplementation for malnourished, HIV-infected adults starting antiretroviral therapy in a resource-constrained setting.

Koethe JR, Marseille E, Giganti MJ, Chi BH, Heimburger D, Stringer JS.

Cost Eff Resour Alloc. 2014 Apr 27;12:10. doi: 10.1186/1478-7547-12-10.

12.

Integrated disease prevention campaigns: assessing country opportunity for implementation via an index approach.

Jiwani A, Matheson A, Kahn JG, Raut A, Verguet S, Marseille E, Walson J.

BMJ Open. 2014 Mar 19;4(3):e004308. doi: 10.1136/bmjopen-2013-004308.

13.

Adult male circumcision in Nyanza, Kenya at scale: the cost and efficiency of alternative service delivery modes.

Marseille E, Kahn JG, Beatty S, Jared M, Perchal P.

BMC Health Serv Res. 2014 Jan 23;14:31. doi: 10.1186/1472-6963-14-31.

14.

Capsule commentary on Long and Stavert, portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.

Kahn JG, Marseille EA.

J Gen Intern Med. 2013 Oct;28(10):1350. doi: 10.1007/s11606-013-2519-9. No abstract available.

15.

Viral load monitoring for antiretroviral therapy in resource-poor settings: an evolving role.

Kahn JG, Marseille EA.

AIDS. 2013 Jun 1;27(9):1509-11. doi: 10.1097/QAD.0b013e3283617544. No abstract available.

PMID:
23759750
16.

Cost-effectiveness analyses of training: a manager's guide.

O'Malley G, Marseille E, Weaver MR.

Hum Resour Health. 2013 May 20;11:20. doi: 10.1186/1478-4491-11-20.

17.

The cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of a new model in India and Israel.

Marseille E, Lohse N, Jiwani A, Hod M, Seshiah V, Yajnik CS, Arora GP, Balaji V, Henriksen O, Lieberman N, Chen R, Damm P, Metzger BE, Kahn JG.

J Matern Fetal Neonatal Med. 2013 May;26(8):802-10. doi: 10.3109/14767058.2013.765845.

PMID:
23311860
18.

Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia.

Marseille E, Giganti MJ, Mwango A, Chisembele-Taylor A, Mulenga L, Over M, Kahn JG, Stringer JS.

PLoS One. 2012;7(12):e51993. doi: 10.1371/journal.pone.0051993.

19.

Case management to improve adherence for HIV-infected patients receiving antiretroviral therapy in Ethiopia: a micro-costing study.

Marseille EA, Kevany S, Ahmed I, Feleke G, Graham B, Heller T, Kahn JG, Reyes M.

Cost Eff Resour Alloc. 2011 Dec 20;9:18. doi: 10.1186/1478-7547-9-18.

20.

Development of a model to assess the cost-effectiveness of gestational diabetes mellitus screening and lifestyle change for the prevention of type 2 diabetes mellitus.

Lohse N, Marseille E, Kahn JG.

Int J Gynaecol Obstet. 2011 Nov;115 Suppl 1:S20-5. doi: 10.1016/S0020-7292(11)60007-6.

PMID:
22099435
Items per page

Supplemental Content

Loading ...
Support Center